STAT News

STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more

Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal

作者 STAT News

1 分钟阅读
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察